A phase II study of WT1-W10 peptide vaccine monotherapy for patients with previously-treated advanced Non-Small Cell Lung Cancer

Phase 2

• Conditions: on-Small Cell Lung Cancer

• Registration Number: JPRN-UMIN000013742
• Lead Sponsor: Kochi University, School of Medicine, Department of Hematology and Resporatory Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-05-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with active concomitant malignancy. 2) Patients with active and severe infection, requiring intravenous antibiotics and/or anti fungal agents. 3) Patients with active lung disease such as idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, or drug-induced pneumonitis, and considered as inappropriate for the study by the physicians. 4) Patients with uncontrollable complications (e.g. uncontrollable heart disease, uncontrollable effusion and/or pericardial effusion, symptomatic brain metastasis, severe arrhythmia, and so on). 5) Pregnancy or lactation. 6) Patients with mental disorder, and considered as inappropriate for the study by the physicians. 7) Inappropriate patients for this study judged by the physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified